COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 3 of 4 for:    ACE-083

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02927080
Recruitment Status : Terminated (Investigation of ACE-083 for use in patients with FSHD is being discontinued as it did not achieve functional secondary endpoints in the A083-02 trial.)
First Posted : October 6, 2016
Last Update Posted : November 6, 2019
Information provided by (Responsible Party):
Acceleron Pharma, Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : September 17, 2019
Actual Study Completion Date : October 9, 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 18, 2020
October 15, 2020
2 November 9, 2020